Ultrasound and clinical investigation of hepatosplenic schistosomiasis: Evaluation of splenomegaly and liver fibrosis four years after mass chemotherapy with oxamniquine

American Journal of Tropical Medicine and Hygiene

Volumn 74, Issue 1, 2006, Pages 103-107

  Cota, Gláucia Fernandes ^a,b   Pinto Silva, Rogério Augusto ^a,b   Antunes, Carlos Maurício Figueiredo ^a,b   Lambertucci, José Roberto ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

OXAMNIQUINE; ANTISCHISTOSOMAL AGENT;

ABDOMINAL RADIOGRAPHY; ADOLESCENT; ADULT; ALCOHOL ABUSE; ARTICLE; BRAZIL; CONTROLLED STUDY; FEMALE; HEPATOSPLENIC SCHISTOSOMIASIS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SINGLE DRUG DOSE; SPLENOMEGALY; TREATMENT OUTCOME; ALCOHOLISM; ECHOGRAPHY; LIVER CIRRHOSIS; MULTIVARIATE ANALYSIS; STATISTICAL MODEL;

ADOLESCENT; ADULT; ALCOHOLISM; FEMALE; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; OXAMNIQUINE; SCHISTOSOMIASIS; SCHISTOSOMICIDES; SPLENOMEGALY;

EID: 33646012628     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2006.74.103     Document Type: Article

References (30)

1. Andrade ZA, 1987. Pathogenesis of pipe-stem fibrosis of the liver: experimental observation on murine schistosomiasis. Mem Inst Oswaldo Cruz 82: 325-334.
2. Andrade ZA, Grimaud JA, 1986. Evolution of schistosomal hepatic lesions in mice after curative chemotherapy. Am J Pathol 124: 59-65.
3. Morcos SH, Mansour MM, Khayyal MT, Saleh S, Ishak EA, Girgis NI, 1992. Evaluation of hepatic fibrosis after oxamniquine therapy of murine schistosomiais. Ann Trop Med Parasitol 86: 511-516.
4. Costa G, Aguiar BG, Coelho PM, Cunha-Melo JR, 2003. On the increase of portal pressure during the acute and chronic phases of murine schistosomiasis mansoni and its reversibility after treatment with oxamniquine. Acta Trop 89: 1-16.
5. Homeida MA, El Tom I, Nash T, Bennett JL, 1991. Association of the therapeutic activity of praziquantel with the reversal of Symmer's fibrosis induced by Schistosoma mansoni. Am J Trop Med Hyg 45: 360-365.
6. Doehring-Schwerdtfeger E, Abdel-Rahim IM, Kardorff R, Kaiser C, Franke D, Schlake J, Richter J, Elsheikh M, Mohamed-Ali Q, Ehrich JH, 1992. Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity twenty-three months after treatment with praziquantel. Am J Trop Med Hyg 46: 409-415.
7. Boisier P, Ramarokoto CE, Ravaoalimalala VE, Rabarijaona L, Serieye J, Roux J, Esterre P, 1998. Reversibility of Schistosoma mansoni-associated morbidity after yearly mass praziquantel therapy: ultrasonographic assessment. Trans R Soc Trop Med Hyg 92: 451-453.
8. Frenzel K, Grigull L, Odongo-Aginya E, Ndugwa CM, Loron-Lakwo T, Schweigmann U, Vester U, Spannbrucker N, Doehring E, 1999. Evidence for a long-term effect of a single dose of praziquantel on Schistosoma mansoni-induced hepatosplenic lesions in northern Uganda. Am J Trop Med Hyg 60: 927-931.
9. De Jesus AR, Miranda DG, Miranda RG, Araújo I, Magalhães A, Bacellar M, Carvalho EM, 2000. Morbidity associated with Schistosoma mansoni infection determined by ultrasound in an endemic area of Brazil, Caatinga do Moura. Am J Trop Med Hyg 63: 1-4.
10. Skinner HA, Holt HA, Schuller R, Israel Y, 1984. Identification of alcohol abuse using laboratory tests and a history of trauma. Ann Intern Med 101: 847-851.
11. Pinto-Silva RA, Abrantes WL, Antunes CM, Lambertucci JR, 1994. Sonographic features of portal hypertension in schistosomiasis mansoni. Rev Inst Med Trop de São Paulo 36: 355-361.
12. WHO Niamey Working Group, 2000. Ultrasound in Schistosomiasis - A Practical Guide to the Standardized Use of Ultrasonography for the Assessment of Schistosomiasis-Related Morbidity (Revised and Update). Second International Workshop, October 22-26, 1996, Niamey, Niger and Satellite Symposium on Ultrasound Methodology in Schistosoma mansoni infection, October 19-24, 1997, Belo Horizonte, Brazil. World Health Organization/TDR/STR/ SCH/00.1, Geneva, Switzerland, 2001.
13. Lambertucci JR, Cota GF, Pinto-Silva RA, Serufo JC, Gersparcher-Lara R, Drummond SC, Antunes CM, Nobre V, Rayes A, 2001. Hepatosplenic schistosomiasis in field-based studies: a combined clinical and ultrasonographic definition. Mem Inst Oswaldo Cruz 96: 147-150.
14. Richter J, Domingues AL, Barata CH, Prata AR, Lambertucci RJ, 2001. Report of the second satellite symposium on ultrasound in schistosomiasis. Mem Inst Oswaldo Cruz 96 (Suppl): 151-156.
15. Lambertucci JR, Serufo JC, Gersparcher-Lara R, Rayes AA, Teixeira R, Nobre V, Antunes C, 2000. Schistosoma mansoni: assessment of morbidity before and after control. Acta Trop 77: 101-109.
16. Karanja DMS, Hightower AW, Colley DG, Mwinzi PNM, Galil K, Andove J, Secor WE, 2002. Resistance to reinfection with Schistosoma mansoni in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study. Lancet 360: 592-596.
17. Afdhal NH, Nunes D, 2004. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 99: 1160-1174.
18. Oberti F, Valsesia E, Rousselet PC, Bedossa P, Aube C, Gallois Y, Rifflet H, Maiga MY, Penneau-Fontbonne D, Cales P, 1997. Nonivasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 113: 1609-1616.
19. Bina JC, 1983. A regressão da hepatoesplenomegalia pelo tratamento específico da esquistossomose. Rev Soc Bras Med Trop 16: 213-218.
20. Dietze R, Prata A, 1986. Rate of reversion of hepatosplenic schistosomiasis after specific therapy. Rev Soc Bras Med Trop 19: 69-73.
21. Barbosa FS, 1966. Morbidade da esquistossomose. Rev Bras Malariol D Trop 3: 159-163.
22. Gerspacher-Lara R, Pinto-Silva RA, Serufo JC, Rayes AAM, Drummond SC, Lambertucci JR, 1998. Splenic palpation for the evaluation of morbidity due to schistosomiasis mansoni. Mem Inst Oswaldo Cruz 93: 245-248.
23. Lambertucci JR, Gerspacher-Lara R, Pinto-Silva RA, Barbosa MM, Teixeira R, Barbosa HF, Serufo JC, Rezende DF, Drummond SC, Rayes AA, 1996. The Queixadinha Project: morbidity and control of schistosomiasis in an endemic area in the northeast of Minas Gerais, Brazil. Rev Soc Bras Med Trop 29: 127-135.
24. Homeida M, Ahmed S, Dafalla A, Suliman S, El Tom I, Nash T, Bennett JL, 1988. Morbidity associated with Schistosoma mansoni infections as determined by ultrasound: a study in Gezira, Sudan. Am J Trop Med Hyg 39: 196-201.
25. Serufo JC, Antunes CM, Pinto-Silva RA, Gersparcher-Lara R, Rayes AAM, Drummond SC, Reis CMF, Martins MJ, Mingoti AS, Lambertucci JR, 1998. Chronic carriers of hepatitis B surface antigen in an endemic area for schistomsomiais mansoni in Brazil. Mem Inst Oswaldo Cruz 93: 249-253.
26. Lambertucci JR, Greco DB, Pedroso ER, da Costa Rocha MO, Salazar HM, de Lima DP, 1982. A double blind trial with oxamniquine in chronic schistosomiasis mansoni. Trans R Soc Trop Med Hyg 76: 751-755.
27. Katz N, Rocha RS, Lambertucci JR, Greco DB, Pedroso ER, Rocha MO, Flan S, 1983. Clinical trial with oxamniquine and praziquantel in the acute and chronic phases of schistosomiasis mansoni. Rev Inst Med Trop São Paulo 25: 173-177.
28. Orrego H, Israel Y, Crossley IR, Mahmound AA, Peters PA, Varghese G, Wanless IR, 1981. Effect of chronic alcohol intake on hepatic fibrosis and granulomas in murine schistosomiasis mansoni. Hepatology 1: 416-418.
29. Houston S, Munjoma M, Kanyimo K, Davidson RN, Flowerdew G, 1993. Use of ultrasound in a study of schistosomal periportal fibrosis in rural Zimbabwe, 1993. Acta Trop 53: 51-58.
30. Liu Y, Yuan HC, Lin DD, Hu F, Zhao GM, Giang QW, Zhang SJ, 2000. Studies on risk factors for liver fibrosis of schistosomiasis japonica. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 18: 18-20.